Renaissance Technologies’s Matinas BioPharma MTNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-4,736
| Closed | -$43.5K | – | 3421 |
|
|
2026
Q2 | $43.5K | Buy |
4,736
+2,831
| +149% | +$27.4K | ﹤0.01% | 3058 |
|
|
2026
Q1 | $14.3K | Sell |
1,905
-26
| -1% | -$244 | ﹤0.01% | 3188 |
|
|
2025
Q4 | $17K | Buy |
1,931
+46
| +2% | +$813 | ﹤0.01% | 3154 |
|
|
2025
Q3 | $53.4K | Buy |
1,885
+240
| +15% | +$5.17K | ﹤0.01% | 3333 |
|
|
2025
Q2 | $22K | Buy |
1,645
+154
| +10% | +$1.69K | ﹤0.01% | 3466 |
|
|
2025
Q1 | $11.6K | Buy |
1,491
+280
| +23% | +$2.49K | ﹤0.01% | 3387 |
|
|
2024
Q4 | $9.27K | Buy |
+1,211
| New | +$27.6K | ﹤0.01% | 3521 |
|
|
2024
Q3 | – | Sell |
-596
| Closed | -$70.8K | – | 3764 |
|
|
2024
Q2 | $70.8K | Buy |
596
+44
| +8% | +$5.98K | ﹤0.01% | 3243 |
|
|
2024
Q1 | $112K | Buy |
552
+56
| +11% | +$10K | ﹤0.01% | 3348 |
|
|
2023
Q4 | $80K | Buy |
496
+210
| +73% | +$35.6K | ﹤0.01% | 3359 |
|
|
2023
Q3 | $28K | Buy |
286
+91
| +47% | +$16.8K | ﹤0.01% | 3482 |
|
|
2023
Q2 | $53K | Sell |
195
-34
| -15% | -$11.9K | ﹤0.01% | 3605 |
|
|
2023
Q1 | $81K | Buy |
229
+68
| +42% | +$25.8K | ﹤0.01% | 3551 |
|
|
2022
Q4 | $61K | Buy |
161
+116
| +258% | +$57.9K | ﹤0.01% | 3761 |
|
|
2022
Q3 | $21K | Buy |
+45
| New | +$26.5K | ﹤0.01% | 3892 |
|
|
2021
Q3 | – | Sell |
-812
| Closed | -$472K | – | 3709 |
|
|
2021
Q2 | $472K | Buy |
812
+625
| +334% | +$403K | ﹤0.01% | 2985 |
|
|
2021
Q1 | $147K | Sell |
187
-1,439
| -88% | -$1.45M | ﹤0.01% | 3190 |
|
|
2020
Q4 | $1.66M | Buy |
+1,626
| New | +$1.13M | ﹤0.01% | 2233 |
|
|
2020
Q3 | – | Sell |
-356
| Closed | -$206K | – | 3568 |
|
|
2020
Q2 | $206K | Sell |
356
-1,010
| -74% | -$581K | ﹤0.01% | 3149 |
|
|
2020
Q1 | $615K | Buy |
1,366
+969
| +244% | +$878K | ﹤0.01% | 2657 |
|
|
2019
Q4 | $676K | Buy |
+397
| New | +$345K | ﹤0.01% | 2790 |
|
|
2019
Q2 | – | Sell |
-337
| Closed | -$276K | – | 3688 |
|
|
2019
Q1 | $276K | Buy |
+337
| New | +$272K | ﹤0.01% | 3120 |
|
|
2018
Q4 | – | Sell |
-180
| Closed | -$124K | – | 3524 |
|
|
2018
Q3 | $124K | Buy |
180
+138
| +329% | +$44.5K | ﹤0.01% | 3222 |
|
|
2018
Q2 | $14K | Buy |
+42
| New | +$18.2K | ﹤0.01% | 3222 |
|
Other funds holding MTNB
Renaissance Technologies's MTNB Position: Q3 2026 in Review
Renaissance Technologies sold out of Matinas BioPharma (MTNB) in Q3 2026, closing a stake of 4,736 shares — an estimated $43.5K sold.
Renaissance Technologies first reported a position in MTNB in Q2 2018 and held it in 24 quarters. The position peaked at $1.66M in Q4 2020. 8 funds tracked by Wall St. Rank hold MTNB as of Q3 2026.
- Renaissance Technologies reported no remaining Matinas BioPharma position as of Q3 2026 after selling out during the quarter.
- Renaissance Technologies sold 4,736 Matinas BioPharma shares in Q3 2026, an estimated $43.5K.
- Renaissance Technologies first reported a position in Matinas BioPharma in Q2 2018 and held it in 24 quarters.
- Renaissance Technologies's Matinas BioPharma position peaked at $1.66M in Q4 2020.
- 8 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2026.
Based on Renaissance Technologies's 13F filing for Q3 2026, filed 12 Nov 2026.